On April 26, Phase II Laboratory of Weipu Biotechnology was grandly inaugurated at Phase V of Suzhou BioBAY. Baino Chuangrui (Wenzhou) Biotechnology Co., Ltd. (hereinafter referred to as Chuangrui Bio) was invited to the event.

At the opening ceremony, Chuangrui Bio and Weipu Biotechnology held a solemn strategic cooperation signing ceremony. Wang Shumin, CEO of Chuangrui Bio, and Yang Jiajia, CEO of Weipu Biotechnology, signed the strategic cooperation agreement. Going forward, the two parties will actively carry out diversified, extensive and in-depth strategic cooperation to mutually drive rapid business growth and help build a sound interactive model for the industrial ecosystem.

On the afternoon of April 26, the 2024 Biopharmaceutical Technology Exchange Salon, themed "Unite as One, Forge Ahead Together", was successfully held in a hybrid offline and online format.

Seven distinguished guests delivered keynote speeches during the presentation session.

In the panel discussion session, Yang Jiajia, CEO and Chief Scientist of Weipu Biotechnology, moderated the roundtable. The invited panelists included Wang Shumin, CEO of Chuangrui Bio; Zhang Sheng, Quality Director of SinoGene Group; Li Yongyong, Deputy Director of the Materials Institute of the Yangtze River Delta National Technology Innovation Center, Director of the Medical Proof-of-Concept Center and Professor at Tongji University School of Medicine; and Yin Yonghong, Executive Deputy General Manager of Shanghai Huicun Medical Technology Co., Ltd. They jointly discussed the topic “Time to Go Global: Unlocking Challenges of Global Layout for Innovative Pharmaceutical Enterprises”.